阿片类药物使用障碍市场规模、份额和成长分析（按治疗方法、给药途径、分销管道、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，全球鸦片类药物使用障碍市场规模将达到 57 亿美元，到 2025 年将成长至 63.7 亿美元，到 2033 年将成长至 155.6 亿美元，在预测期（2026-2033 年）内复合年增长率为 11.8%。

药物滥用趋势的上升，以及政府为提高公众对阿片类药物使用障碍（OUD）的认识和扩大治疗设施所做的努力，正在显着推动市场需求。这一增长主要源于处方阿片类药物、海洛因和合成药物滥用的增加，促使人们需要更全面的治疗方案。全球对OUD的认识提升以及对治疗方案的优先考虑，在公众和相关人员的支持下，正在创造新的长期成长机会。治疗中心、门诊诊所、远端医疗服务和综合护理计画的激增也提高了治疗的可近性，进一步推动了市场成长。然而，社会污名、发展中地区服务取得有限、治疗费用高昂以及监管障碍等挑战可能会阻碍市场扩张和渗透。

全球阿片类药物使用疾患市场驱动因素

不断增加的研发投入旨在开发新型药物治疗产品，这极大地促进了各种阿片类药物使用障碍的治疗。缓释Buprenornhine注射、创新植入、纳曲酮等新型逆转剂以及联合治疗等进展，为市场相关人员带来了许多机会。此外，这些进展不仅降低了给药频率，还提高了患者的依从性，从而对全球市场前景产生了积极影响。这种对创新的日益重视正在重塑有效治疗方案的格局。

限制全球阿片类药物使用疾患市场的因素

由于社会上对阿片类药物使用障碍的持续污名化，全球阿片类药物使用障碍市场面临严峻挑战。许多鸦片类药物使用障碍患者因担心受到批评、歧视和法律制裁而犹豫不决，不敢寻求治疗。这种恐惧往往导致现有治疗项目和服务的使用率不足。此外，文化障碍和羞耻感也会阻碍患者获得所需的医疗服务，最终抑制市场成长和发展。消除这些社会认知对于提高治疗接受度、为鸦片类药物使用障碍患者提供更有效的医疗保健至关重要。

全球阿片类药物使用疾患市场趋势

全球阿片类药物使用障碍市场正经历着长效和缓释药物的重大转变，这反映了临床医生和患者日益增长的偏好。Buprenornhine注射剂和纳曲酮植入剂等创新治疗方法因其高效性和安全性而备受关注。这些製剂不仅透过减少给药频率来提高患者的用药依从性，还能更稳定地控制症状，进而提高患者的接受度。随着医疗机构越来越多地采用这些先进的治疗方案，对长效疗法的需求有望重塑市场格局，成为有效克服阿片类药物使用障碍的一个充满希望的趋势。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境

全球阿片类药物使用障碍市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 美沙酮
• Buprenornhine
• 纳曲酮
• 其他治疗方法

全球阿片类药物使用障碍市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 注射/植入
• 经皮/其他

全球阿片类药物使用障碍市场规模（按分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 线上/电子商务

全球阿片类药物使用障碍市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 门诊部
• 住院设施/住宅治疗中心
• 远端医疗

全球阿片类药物使用障碍市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Indivior PLC
• Alkermes plc
• Orexo AB
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Camurus AB
• Hikma Pharmaceuticals PLC
• Titan Pharmaceuticals Inc.
• Omeros Corporation
• Mylan NV
• Johnson & Johnson Services, Inc.
• Boehringer Ingelheim GmbH
• Purdue Pharma LP
• ZLB Behring
• Novartis AG
• Mallinckrodt Pharmaceuticals
• Sandoz
• Gilead Sciences Inc.
• ViiV Healthcare
• Camurus AB

结论与建议

Global Opioid Use Disorder Market size was valued at USD 5.7 Billion in 2024 and is poised to grow from USD 6.37 Billion in 2025 to USD 15.56 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).

The increasing incidence of drug abuse, coupled with heightened government initiatives to enhance awareness and expand treatment facilities for opioid use disorder (OUD), is driving significant market demand. This surge is largely fueled by the rising misuse of prescription opioids, heroin, and synthetic drugs, necessitating more comprehensive treatment solutions. Global prioritization of OUD awareness and therapeutic options presents new long-term opportunities, supported by growing public and stakeholder advocacy. The proliferation of treatment centers, outpatient clinics, telehealth services, and integrated care programs has also enhanced access to care, further contributing to market growth. However, challenges such as social stigma, limited access in developing regions, high treatment costs, and regulatory barriers may hinder market expansion and penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Opioid Use Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Opioid Use Disorder Market Segments Analysis

Global Opioid Use Disorder Market is segmented by Treatment, Route of Administration, Distribution Channel, End-User and region. Based on Treatment, the market is segmented into Methadone, Buprenorphine, Naltrexone and Other Therapies. Based on Route of Administration, the market is segmented into Oral, Injectable / Implant and Transdermal / Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online / E-commerce. Based on End-User, the market is segmented into Outpatient Clinics, Inpatient / Residential Treatment Centres and Remote Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Opioid Use Disorder Market

The expansion of investments in research and development aimed at creating new pharmacotherapy products is significantly contributing to the treatment of various opioid use disorders. Advances such as extended-release buprenorphine injections, innovative implants, and novel antagonists like naltrexone, along with combination therapies, are opening up a multitude of opportunities for stakeholders within the market. Furthermore, these advancements not only lead to a reduction in dosing frequency but also enhance patient adherence, thus positively influencing the overall perspective of the global opioid use disorder market. This growing emphasis on innovation is shaping the landscape for effective treatment solutions.

Restraints in the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market faces significant challenges due to the persistent social stigma surrounding this condition. Many individuals grappling with opioid use disorder hesitate to seek treatment due to fears of judgment, discrimination, or potential legal repercussions. This apprehension often leads to underutilization of available treatment programs and services. Furthermore, cultural barriers and feelings of shame can further inhibit individuals from accessing necessary care, ultimately stalling the growth and development of the market. Addressing these societal attitudes is crucial for improving treatment uptake and moving towards a more effective healthcare response for those affected by opioid use disorder.

Market Trends of the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market is experiencing a significant shift toward long-acting and extended-release pharmacotherapies, reflecting a growing preference among clinicians and patients alike. Innovations such as buprenorphine injections and naltrexone implants are gaining traction due to their enhanced efficacy and safety profiles. These formulations not only improve adherence by reducing the frequency of dosing but also provide a more stable management of symptoms, leading to higher patient acceptance. As healthcare providers increasingly adopt these advanced treatment options, the demand for long-acting therapies is poised to reshape the market landscape, highlighting a promising trend in combating opioid use disorders effectively.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Opioid Use Disorder Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Methadone
• Buprenorphine
• Naltrexone
• Other Therapies

Global Opioid Use Disorder Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable / Implant
• Transdermal / Other

Global Opioid Use Disorder Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online / E-commerce

Global Opioid Use Disorder Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Outpatient Clinics
• Inpatient / Residential Treatment Centres
• Remote Care

Global Opioid Use Disorder Market Size & CAGR (2026-2033)

• North America (Treatment, Route of Administration, Distribution Channel, End-User)
  • US
  • Canada
• Europe (Treatment, Route of Administration, Distribution Channel, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Route of Administration, Distribution Channel, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Route of Administration, Distribution Channel, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Indivior PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orexo AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Camurus AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Titan Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omeros Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma L.P.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZLB Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViiV Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Camurus AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations